Low levels of HIF-1 activation were strongly indicative of a favourable prognosis and the data suggest that elevated tumor ascorbate levels could moderate the hypoxic response in breast tumors, with a potential clinical benefit. The gene discussed is SETD2; the disease is breast neoplasm.